EdiGene, a Beijing biopharma using CRISPR/Cas9 genome editing and high throughput genetic screening to discover drug targets, sold its library of knockout (KO) cell lines to Abcam, a Cambridge, UK research tools company. With its gene editing technology, EdiGene has developed a library of over 2,800 single clonal KO cell lines that target 2,600 genes in commonly used human cancer cell lines. The lines are used to validate antibodies and to understand biological pathways and disease models. EdiGene plans to concentrate on its near-clinical stage drug candidates. Financial terms were not disclosed.
Source: China Biotoday
